Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 4,089,003	$ 1,204,924
Marketable securities	1,753,499	640,460
Accounts receivable, net	1,327,780	1,292,445
Due from unconsolidated joint business, net	319,788	283,360
Inventory	918,921	804,022
Other current assets	861,882	446,943
Total current assets	9,270,873	4,672,154
Marketable securities	1,947,354	1,470,652
Property, plant and equipment, net	2,027,821	1,765,683
Intangible assets, net	4,181,245	4,028,507
Goodwill	2,408,854	1,760,249
Investments and other assets	892,221	617,536
Total assets	20,728,368	14,314,781
Current liabilities:
Current portion of notes payable and other financing arrangements	5,171	3,136
Taxes payable	458,672	168,058
Accounts payable	251,228	229,178
Accrued expenses and other	1,918,897	1,819,334
Total current liabilities	2,633,968	2,219,706
Notes payable and other financing arrangements	6,529,275	580,283
Long-term deferred tax liability	136,761	50,656
Other long-term liabilities	861,421	650,096
Total liabilities	$ 10,161,425	$ 3,500,741
Commitments and contingencies
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	$ 0	$ 0
Common stock, par value $0.0005 per share	124	129
Additional paid-in capital	1,342,373	4,196,156
Accumulated other comprehensive loss	(157,416)	(59,488)
Retained earnings	11,999,358	9,283,919
Treasury stock, at cost	(2,611,713)	(2,611,706)
Total Biogen Inc. shareholders’ equity	10,572,726	10,809,010
Noncontrolling interests	(5,783)	5,030
Total equity	10,566,943	10,814,040
Total liabilities and equity	$ 20,728,368	$ 14,314,781